Compare Amphastar Pharmaceuticals Inc (AMPH) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs SiTime Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while SiTime Corporation trades at $669.09 (market cap $20.73B). The key difference: SiTime Corporation is far larger — about 24× Amphastar Pharmaceuticals Inc's market cap, and SiTime Corporation is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | SITM | |
|---|---|---|
Market Cap | $863.95M | $20.73B |
Sector | Health | Technology |
52-Week High | $30.81 | $901.60 |
52-Week Low | $16.87 | $203.06 |
Enterprise Value | $1.26B | $20.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
SITM stock surged 5.5% to $725.28, showing strong momentum with three consecutive quarterly earnings beats and bullish technical indicators. The company reported 127% revenue growth in Q2 2026 and expects further acceleration from AI infrastructure demand and the Renesas acquisition. Despite negative 2025 earnings, profitability improved significantly with net income turning positive in 2026 projections.
Outlook remains positive with 100% analyst buy ratings and $870 consensus target, though premium valuations (P/E 1,148, P/S 39) and execution risks from the Renesas integration warrant caution. AI timing growth presents substantial opportunity, but stock appears fully valued after recent run-up.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
